# Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy

> **NCT03319745** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 23 (actual)

## Conditions studied

- Stage I Bladder Cancer AJCC v8
- Stage II Bladder Cancer AJCC v8
- Stage III Bladder Cancer AJCC v8
- Stage IIIA Bladder Cancer AJCC v8
- Stage IIIB Bladder Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03319745
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-11
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03319745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03319745, "Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03319745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*